Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

115.23
+0.49000.43%
Post-market: 115.690.4600+0.40%19:50 EDT
Volume:910.31K
Turnover:105.35M
Market Cap:12.46B
PE:254.00
High:118.07
Open:114.80
Low:113.98
Close:114.74
52wk High:126.38
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.97
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:17.65
PE(LYR):140.52

Loading ...

Corcept CFO Atabak Mokari sells 40,000 shares for USD 2.8 million

Reuters
·
Jun 04

Corcept Therapeutics - DOJ, California Department of Insurance, and Plaintiff States Decline to Intervene in Lawsuit - SEC Filing

THOMSON REUTERS
·
Jun 03

Corcept Therapeutics Inc: Intends to Defend Against All of Relator's Claims

THOMSON REUTERS
·
Jun 03

Corcept Therapeutics - DOJ Previously Issued Records Subpoena to Corcept in Nov 2021 Regarding Korlym Sales and Promotion - SEC Filing

THOMSON REUTERS
·
Jun 03

Corcept Therapeutics - Relator Serves Corcept With Amended Complaint on June 2, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 03

Corcept says DOJ declines to intervene in Korlym-related qui tam lawsuit

Reuters
·
Jun 03

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon sells 5,000 shares for $325,000

Reuters
·
May 30

Corcept Endocrinology President Sean Maduck sells USD 4.92 million Corcept Therapeutics shares

Reuters
·
May 30

Corcept Therapeutics holds annual shareholder meeting, backs amended 2024 incentive plan

Reuters
·
May 29

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 28

U.S. RESEARCH ROUNDUP-Salesforce, Snowflake, Zscaler

Reuters
·
May 28

Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $135 From $110

THOMSON REUTERS
·
May 28

Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant

TIPRANKS
·
May 27

BRIEF-Corcept To Resubmit NDA For Relacorilant As Treatment For Cushing's Syndrome Patients

Reuters
·
May 27

Corcept plans to resubmit FDA NDA for relacorilant in Cushing’s syndrome after CRL

Reuters
·
May 27

Corcept Therapeutics Inc - FDA Expects Pdufa Date Six Months After Nda Resubmission for Relacorilant

THOMSON REUTERS
·
May 27

Corcept to Resubmit Its New Drug Application for Relacorilant as a Treatment for Patients With Cushing’s Syndrome

THOMSON REUTERS
·
May 27

Does Corcept Therapeutics' (CORT) UBS Upgrade and Insider Gifting Reframe Its Oncology Ambitions?

Simply Wall St.
·
May 18

Corcept Therapeutics Shares Rise After UBS Upgrade

MT Newswires Live
·
May 14